University of Birmingham researchers have developed a Covid-19 test that reduces testing time from 30 minutes to less than five and which they believe is also sufficiently sensitive for delivering accurate results. Click to read more.
Jan 09 2021 Read 345 Times
Revitope Oncology Inc and leading Chinese biopharmaceutical company Junshi Biosciences, are collaborating on the development of precision cancer therapies that harness the body’s immune response to kill cancer cells while leaving healthy body tissues untouched.
The Birmingham spin-out will leverage its proprietary protein engineering platform with Junshi’s novel antibody components to develop first-in-class dual antigen targeting cancer therapies. Revitope will receive up to $160 million per molecule in milestones and royalties on net sales of 10%. Junshi has also committed to acquire a 9.99% stake in Revitope for $10 million.
Revitope’s technology known as the T-cell engager antibody circuit (TEAC), splits antibodies into two halves which are programmed to recognise different antigens. The two halves are inactive until they encounter a cancer cell that is expressing both antigens, when they reunite and direct the body’s immune response to kill
New COVID-19 test gives positive result in just a few minutes medicaldialogues.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicaldialogues.in Daily Mail and Mail on Sunday newspapers.
The development, hailed as a world first, could be the breakthrough to help get crowds back to sporting events and festivals across the UK this summer.
University of Birmingham researchers develop rapid COVID-19 RNA test
6th January 2021
Researchers from the University of Birmingham have created a new RNA test for COVID-19, which they say can reduce the testing time to under five minutes while still delivering accurate results.
The method has been published in a preprint paper on MedRxiv, meaning that it has not yet been peer-reviewed, although the University of Birmingham Enterprise has filed a patent application covering the method and its use in diagnostic equipment.
The Enterprise is also seeking to license the patent for rapid product development.
The preprint paper demonstrates the rapidity and sensitivity of the method using a patient sample RNA provided by Public Health England.